(MENAFN- ProactiveInvestors)New York-listed VolitionRx aims to revolutionise cancer screening and its chief executive Cameron Reynolds explains to Proactive Investors the basics behind the company's technology which works on a 'very very small amount of blood' and is less invasive and more cost-effective than many competing diagnostic processes. Results from trials of the technology have been very encouraging and the European CE mark for the first test – on colorectal cancer – could be secured within a year with approval from the US's Food and Drug Administration set to follow the following year. With 93mln people undergoing these diagnostic tests every two or three years the market for the company's products is enormous.
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.